CARDIOVASCULAR DISEASES AT GOUT

V. Ye.  Kondratiuk; O.V.  Berzin

doi:10.32345/USMYJ.3(108).2018.66-70

V. Ye. Kondratiuk Bogomolets National Medical University, Kyiv, Ukraine
O.V. Berzin Bogomolets National Medical University, Kyiv, Ukraine

DOI: https://doi.org/10.32345/USMYJ.3(108).2018.66-70

Keywords: gout, cardiovascular diseases, allopurinol, febuxostat

Abstract

The article covers data on the study of the main risk factors and the search for prognostic indicators of cardiovascular risk in gout, a modern understanding of the main mechanisms of influencing the risk of cardiovascular diseases. Data on the efficacy and safety of anti-rheumatic therapy in gout from the point of view of cardiovascular risk are presented.

References

Кондратюк В.Є., Тарасенко О.М. (2016) Гіперурикемія та подагра: сучасний стан проблеми. Укр. ревматол. журн., 3(65): 30—37.

ШубаНМ., Воронова Т.Д., Литвиненко С.В. (2015) Роль гипе- рурикемии в развитии кардиоваскулярной патологии. Укр. ревматол. журн., 2(68): 39-46.

Логинова Т.К., Шостак Н.А., Копелев А А. (2008) Поражение сердца при подагре. Клиницист, 3: 20—24.

Singh J.A. (2015) When gout goes to the heart: does gout equal a cardiovascular disease risk factor? Annals of the Rheumatic Diseases, 74: 631-634.

Kuo C, Grainge MJ, Mallen C, et al. (2016) Comorbidities in patients with gout prior to and following diagnosis: case-control study Annals of the Rheumatic Diseases, 75: 210—217.

Desai RJ, Franklin JM, Spoendlin-AUen J, Solomon DH et al. (2018) An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. PLoS ONE 13(2): e0193622.

Mitchell S, Liedgens H, Johannes E (2017) THU0462 Mortality in patients with gout: a systematic review Annals of the Rheumatic Diseases; 76:382.

NossentJ, Raymond W, DivitiniM et al (2016) OP0018 Hyperuricemia Increases Mortality Only in Patients with Gout and Existing Cardiovascular isease. A Prospective Analysis from The Busselton Health Study Annals of the Rheumatic Diseases . Annals of the Rheumatic Diseases, 75: 59-60.

Richette P, Perez-Ruiz F, Doherty M, et al. (2014) Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol, 10:654—61.

Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104—10.

Perez-Ruiz F, Martunez-Indart L, Carmona L, et al. (2014) Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Annals of the Rheumatic Diseases, 73:177—182.

Vincent Z L., Gamble G, House M. et al. (2017) Predictors of Mortality in People with Recent-onset Gout: A Prospective Observational Study. The Journal of Rheumatology, March, 44 (3) 368—373.

Krishnan E (2012) Gout and the risk for incident heart failure and systolic dysfunction BMJ Open, 2:e000282. doi: 10.1136/bmjopen-2011— 000282

Seminog OO, Goldacre MJ. (2013) Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford). 2013;52(12):2251—2259.

Kuo CF, Yu KH, See EC, et al. (2013) Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 2013;52: 111—117.

Bredemeier M., Lopes L. M., Eisenreich M. A. et al. (2018). Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, Feb 7;18f7J:24.

Choi HK, Curhan G. (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation.; 116(8): 894—900.

Choi HK, Ford ES, Li C, Curhan G. (2007) Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition. Arthritis Rheum. Feb 15;57(l):109-15.

DAgostino RB Sr, Vasan RS, Pencina MJ, et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation.; 117:743-53.

Conroy RM, Pyorala K, FitzgeraldAP, et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J.;24:987-1003.

Kuo CF, See LC, Luo SF et al. (2010) Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). Jan;49(l):141-6.

ЕлисеевM.C., ДенисовН.С., МаркеловаE.H. и др. (2017) Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного исследования. Терапевт, архив., 05: 10—19.

Clarson LE, Hider SL, Belcher J, et al.( 2015) Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink Annals of the Rheumatic Diseases ;74:642—647.

Kuo C.F., See L.C., Yu KH. et al. (2013) Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality.Rheumatology (Oxford), 52: 127—134.

Stack AG, Hanley A, Casserly LF et al.( 2013) Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM. Jul; 106(7):647-58

Thanassoulis G, Brophy JM, Richard H, Pilote L. (2010) Gout, allopurinol use, and heart failure outcomes. Arch Intern Med.; 170(15): 1358-1364.

Carter JD, Patelli M, Anderson SR et al. (2015) An MRI assessmentof chronic synovial-based inflammation in gout and its correlation with serum urate levels. Clin Rheumatol.;34(2):345—351.

Chowalloor P, Cheah P, Keen HI. (2014) Subclinical Synovial Inflammation in Gout. Arthritis & Rheumatology. ACR;66(11) (Suppl.) :S64.

Кардіоваскулярний ризик та ревматологічні захворювання кардіоревматологічний синдром): монографія / О.В. Курята, О.Ю. Сіренко; ДЗ «Дніпропетровська медична академія МОЗ України». — Дніпро: Герда, 2017. — 88 с.

Peters MJ, Symmons DP, McCarey D, et al. (2010) EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis.;69(2):325—331.

Agca R, Heslinga SC, Rollefstad S, et al. (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update Annals of the Rheumatic Diseases; 76:17—28.

RockKL, Kataoka H, Lai JJ. (2013) Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol.;9(1): 13—23.

Krishnan E, Pandya BJ, Chung L, Dabbous O. (2011) Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Res Ther.; 13(2):R66.

Stamp LK, Turner R, Khalilova IS, et al. (2014) Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. Rheumatology (Oxford); 53:1958-1965.

Feig DI, Kang DH, Johnson RJ. (2008) Uric acid and cardiovascular risk. N Engl J Med.;359(17):1811—1821.

So A, Thorens В . (2016) Uric acid transport and disease. J Clin Invest 2010; Jun;120(6):1791-9.

Vassalle C, MazzoneA, Sabatino L, Carpeggiani C. Uric Acid for Cardiovascular Risk: Dr.Jekyll or Mr. Hide? Diseases, 4 (1), 12.

Елисеев M.C., Желябина O.B., Маркелова Е.И. и др., (2016) Оценка кардиоваскулярного риска при применении ингибиторов интерлейкина 1 у больных тяжелой тофусной подагрой. Современная ревматология, 10(1): 7—14.

Richette Р, Doherty М., Pascual Е. et al. (2016) 2016 updated EULAR evidence-based recommendations for the management of goutAnn. Rheum. Dis., 0: 1—14

Елисеев M.C. (2017) Обновленные рекомендации EULAR no лечению подагры. Комментарии к некоторым позициям. Научно- практическая ревматология, 55(6): 600—609.

Kim, S. С., Schneeweiss, S., Choudhry, N., Liu, J., Glynn, R. J., & Solomon, D. H. (2015).Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. The American Journal of Medicine, 128(6), 653.e7-653.el6.

deAbajo F, GilM, Rodriguez A, et al. (2015) Allopurinol use and risk of nonfatal acute myocardial infarction. Heart;101:679—85.

Singh J.A., Cleveland J. (2017) Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data. BMC Med., 15(1):59. Published 2017Mar 22.

Edwards N.L. (2009) Febuxostat: a new treatment for hyperuricaemia in gout.Rheumatology (Oxford). May;48 Suppl 2: H15-H19.

Frampton J.E. (2015). Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs, 75(4): 427—438. (укр феб)

Kim S, Kim HJ, Ahn HS, et al.( 2017) Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis. Kidney Res Clin Pract.;36(3J: 274-281

LiuX, Liu K, Sun Q. et al. (2018) Efficacy and safety offebuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta-analysis. Exp TherMed. Sep;16(3):1859-1865.

Foody J, Turpin RS, Tidwell BA, Lawrence D, Schulman KL. (2017) Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor. American Health & Drug Benefits. ;10(8):393-401.

Tani S, Nagao K, Hirayama A.(2015) Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study. Clin Drug Investig. Dec;35(12):823-31.

Aschenbrenner D.S.(2018) Risk of Heart-Related Death From Gout Medication AJN, American Journal of Nursing: March — Volume 118 — Issue 3 — p 23.

White WB, Saag KG, Becker MA, et al.(2018) Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med; 378:1200-1210.